Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 4, 2025

InVivoPlus mouse IgG2b isotype control

RRID:AB_1107791
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0086, RRID:AB_1107791)

Antibody Information

URL: http://antibodyregistry.org/AB_1107791

Proper Citation: (Bio X Cell Cat# BE0086, RRID:AB_1107791)

Target Antigen: Unknown Specificity

Host Organism: mouse

Clonality: isotype control

Comments: Consolidation on 12/2021: AB_1107791, AB_2894741.

Antibody Name: InVivoPlus mouse IgG2b isotype control

Description: This isotype control targets Unknown Specificity

Clone ID: clone MPC-11

Antibody ID: AB_1107791

Vendor: Bio X Cell

Catalog Number: BE0086

Alternative Catalog Numbers: BE0086-5MG, BE0086-50MG, BP0086-100MG, BE0086-25MG, BE0086-100MG, BP0086-25MG, BP0086-50MG, BP0086-5MG, BE0086-1MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T045149+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus mouse IgG2b isotype control.

No alerts have been found for InVivoPlus mouse IgG2b isotype control.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Cha J, et al. (2024) Skin microbe-dependent TSLP-ILC2 priming axis in early life is co-opted in allergic inflammation. Cell host & microbe, 32(2), 244.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity, 57(3), 528.

Maxwell MB, et al. (2024) ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell, 187(13), 3390.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell, 41(11), 1911.

Freshour SL, et al. (2023) Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. iScience, 26(10), 107937.

Bender MJ, et al. (2023) Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell, 186(9), 1846.

Tibbs TN, et al. (2023) Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses. iScience, 26(11), 108348.

Taifour T, et al. (2023) The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity, 56(12), 2755.

Wang J, et al. (2023) Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. iScience, 26(12), 108414.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent

dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer cell, 41(2), 235.

Denk D, et al. (2022) Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity, 55(11), 2059.

Guo D, et al. (2022) Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I?B?. Cell metabolism, 34(9), 1312.

Blanchard L, et al. (2022) Flow cytometry analysis of endothelial cells and subsets of exhausted CD8+ T cells in murine tumor models. STAR protocols, 3(2), 101444.

Yuan X, et al. (2022) Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer discovery, 12(7), 1742.

Wu MJ, et al. (2022) Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer discovery, 12(3), 812.

Asrir A, et al. (2022) Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer cell, 40(3), 318.

Dai X, et al. (2021) Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular cell, 81(11), 2317.

Giampazolias E, et al. (2021) Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell, 184(15), 4016.

O'Connor RA, et al. (2021) T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. Oncoimmunology, 10(1), 1940675.

Gabriely G, et al. (2021) Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells. iScience, 24(11), 103347.